Strong H1 profit and new product approvals offset major shareholder selling
H1 profit jumps 71% on higher sales and margins SWS reported first-half 2026 revenue up 29.8% to 464 million yuan and net profit up 71.46% to 94.37 million yuan. Higher sales of self-made blood purification consumables and better gross margin drove the gain, showing the core business is growing profitably.
This is the main positive force behind the stock, showing strong underlying business momentum.
New product approvals expand market access A subsidiary received a medical device registration certificate for single-use hemodialysis blood tubing and a change filing for continuous blood purification tubing. These approvals let SWS sell more products in hospitals, supporting future revenue growth.
New product approvals are a concrete growth driver that can lift future sales and investor confidence.
High dividend payout signals confidence and cash returns SWS plans to pay 2 yuan per 10 shares, a 94.83% payout of first-half profit. A high dividend returns cash to shareholders and signals management's confidence in steady earnings, which can attract income-focused investors.
The dividend is a new capital return event that supports the stock's appeal and shows financial health.
Major shareholder plans to sell up to 4.03% stake A major shareholder plans to cut its stake by up to 4.03%, worth about 200 million yuan, starting September 3. This is the third reduction plan in a year, which can pressure the stock price by increasing the number of shares for sale.
This is the main counterweight to the positive news, explaining why the stock may face selling pressure.